Autres langues PMV Pharmaceuticals, Inc.

Actions

PMVP

US69353Y1038

Temps réel estimé Cboe BZX Autres places de cotation 21:20:01 26/04/2024			Varia. 5j.	Varia. 1 janv.
1,735 ^USD	+1,46 %		+7,45 %	-44,19 %

12/04	PMV PHARMACEUTICALS, INC. : Jefferies & Co. favorable sur le dossier	ZM
27/03	PMV Pharmaceuticals, Inc. Annonce le dosage du premier patient dans l'étude mondiale de phase 2 PYNNACLE pour Rezatapopt dans les tumeurs solides TP53 Y220c-positives.	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors	27/03
PMV Pharmaceuticals, Inc. Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220c-Positive Solid Tumors	27/03
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer	18/03
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer	18/03
North American Morning Briefing : Stock Futures -2-	06/03
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights	29/02
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference	26/02
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway	18/01
PMV Pharmaceuticals, Inc. Announces Workforce Reduction of Approximately 30%	18/01
MORNING BRIEFING - USA/Asien	08/01
PMV Pharmaceuticals Names Michael Carulli as CFO; Phase 2 Trial of Tumor Treatment on Track	05/01
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development	05/01
PMV Pharmaceuticals, Inc. Announces Chief Financial Officer Changes	05/01
PMV Pharmaceuticals, Inc. Announces Executive Changes	05/01
PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from NASDAQ Biotechnology Index	15/12
PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights	09/11
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11
PMV Pharmaceuticals Says Updated Trial Data Show Cancer Therapy Induces Anti-Tumor Activity; Shares Fall	12/10/23
PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation	12/10/23

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues PMV Pharmaceuticals, Inc.

Actions

PMVP

US69353Y1038

Autres langues

Filtres